Pediatric relapsed acute myeloid leukemia: a systematic review

Area of Science:

• Pediatric Hematology/Oncology
• Cancer Treatment Outcomes
• Systematic Review Methodology

Background:

• Pediatric relapsed acute myeloid leukemia (AML) has a poor prognosis despite intensive therapies.
• Optimal treatment strategies and prognostic factors for relapsed pediatric AML are not well-defined.
• There is a significant lack of randomized clinical trials in this area.

Purpose of the Study:

• To systematically review existing literature on treatment outcomes for pediatric patients with relapsed AML.
• To identify prognostic factors and evaluate the effectiveness of different therapeutic approaches.
• To highlight gaps in knowledge and suggest future research directions.

Main Methods:

• Systematic literature search of PubMed and Embase.com.
• Inclusion criteria: pediatric patients (<21 years) with relapsed AML, reporting clinical outcomes.
• Analysis of 12 selected studies focusing on second complete remission (CR2), disease-free survival (DFS), event-free survival (EFS), and overall survival (OS).

Main Results:

• No standard treatment exists for relapsed pediatric AML.
• Reported CR2 rates averaged 64% (range 50-75%), and 2- to 10-year OS rates averaged 31% (range 16-43%).
• Chemotherapy alone in first complete remission (CR1) may yield better outcomes than allogeneic stem cell transplant (allo-SCT) in CR1; allo-SCT is effective for CR2 consolidation.
• Duration of CR1 was the most significant prognostic factor identified.

Conclusions:

• Pediatric relapsed AML treatment requires further research to establish standardized, risk-stratified therapies.
• Improved understanding of prognostic factors and development of more effective, less toxic treatments are crucial.
• International collaboration for large, randomized clinical trials is essential to address knowledge gaps.